Healixa Inc. announces that Christopher Galliano will join its Board of Directors as a non-executive independent Director effective January 11, 2022, demonstrating the company's focus on corporate governance, growth and national list requirements. Mr. Galliano currently serves as Chief Technology Officer and Co-Founder of Skymount Medical, where he co-authored over 6 patents in artificial intelligence based drug discovery and leads the day to day research to construct an oral therapeutic for COVID-19 and 12 other active inventions/pharmaceutical developments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0749 USD | -6.20% | -6.38% | -73.25% |
1st Jan change | Capi. | |
---|---|---|
-73.25% | 53.34M | |
+9.97% | 3,073B | |
+8.99% | 85.98B | |
+5.06% | 78.37B | |
-16.81% | 52.7B | |
+24.17% | 47.48B | |
+29.39% | 45.54B | |
-32.98% | 41.5B | |
+71.23% | 39.83B | |
+1.67% | 28.05B |
- Stock Market
- Equities
- EMOR Stock
- News Healixa Inc.
- Healixa, Inc. Appoints Christopher Galliano as Independent Director to its Board